Anti-GPCR GPR17 antibody [EPR26423-34],Abcam,AB316105

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Mouse, Rat, Human

Application

IHC-Fr, mIHC, IHC-P, IP, ICC/IF, Flow Cyt (Intra), WB

Platform ID

BAB759758343

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Abcam

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Email:

[email protected]

Product Specifications
Scientific Background

Specifications

NameAnti-GPCR GPR17 antibody [EPR26423-34]
Cat. No.AB316105
HostRabbit
IsotypeIgG
ReactivityMouse, Rat, Human
ApplicationIHC-Fr, mIHC, IHC-P, IP, ICC/IF, Flow Cyt (Intra), WB
ClonalityMonoclonal
Clone NumberEPR26423-34
Concentration0.506 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Dual specificity receptor for uracil nucleotides and cysteinyl leukotrienes (CysLTs). Signals through G(i) and inhibition of adenylyl cyclase. May mediate brain damage by nucleotides and CysLTs following ischemia (By similarity). See full target information Gpr17

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.